1. Home
  2. POLE vs NMRA Comparison

POLE vs NMRA Comparison

Compare POLE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POLE
  • NMRA
  • Stock Information
  • Founded
  • POLE 2024
  • NMRA 2019
  • Country
  • POLE United States
  • NMRA United States
  • Employees
  • POLE N/A
  • NMRA N/A
  • Industry
  • POLE
  • NMRA
  • Sector
  • POLE
  • NMRA
  • Exchange
  • POLE NYSE
  • NMRA Nasdaq
  • Market Cap
  • POLE 296.0M
  • NMRA 287.6M
  • IPO Year
  • POLE 2024
  • NMRA 2023
  • Fundamental
  • Price
  • POLE $10.12
  • NMRA $1.16
  • Analyst Decision
  • POLE
  • NMRA Buy
  • Analyst Count
  • POLE 0
  • NMRA 8
  • Target Price
  • POLE N/A
  • NMRA $10.14
  • AVG Volume (30 Days)
  • POLE 3.8K
  • NMRA 1.3M
  • Earning Date
  • POLE 01-01-0001
  • NMRA 03-03-2025
  • Dividend Yield
  • POLE N/A
  • NMRA N/A
  • EPS Growth
  • POLE N/A
  • NMRA N/A
  • EPS
  • POLE N/A
  • NMRA N/A
  • Revenue
  • POLE N/A
  • NMRA N/A
  • Revenue This Year
  • POLE N/A
  • NMRA N/A
  • Revenue Next Year
  • POLE N/A
  • NMRA N/A
  • P/E Ratio
  • POLE N/A
  • NMRA N/A
  • Revenue Growth
  • POLE N/A
  • NMRA N/A
  • 52 Week Low
  • POLE $9.94
  • NMRA $1.13
  • 52 Week High
  • POLE $11.16
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • POLE N/A
  • NMRA 28.13
  • Support Level
  • POLE N/A
  • NMRA $1.13
  • Resistance Level
  • POLE N/A
  • NMRA $1.48
  • Average True Range (ATR)
  • POLE 0.00
  • NMRA 0.13
  • MACD
  • POLE 0.00
  • NMRA 0.06
  • Stochastic Oscillator
  • POLE 0.00
  • NMRA 17.03

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: